{
  "report_rows": [
    {
      "kpi": "Non-GAAP EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.67 vs. cons $1.60",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$11.82B vs. cons $11.74B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Eliquis worldwide revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.84B vs. cons $3.81B",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 revenue guidance",
      "prediction": "BETTER",
      "answer": "guide ~$47.2B vs. cons $46.8B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 non-GAAP EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$6.30 vs. cons $6.20 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Eliquis worldwide growth outlook",
      "prediction": "UNCHANGED",
      "answer": "guide ~12.5% vs. cons 12.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 non-GAAP gross-margin outlook",
      "prediction": "UNCHANGED",
      "answer": "guide ~69.5% vs. cons 69.5% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.4,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A ~$0.07 EPS beat versus $1.60 consensus plus an implied FY2026 EPS guide of ~$6.30 versus $6.20 should support upward full-year estimates; maintained Eliquis growth of ~12.5% versus 12.5% consensus limits concern that the expected inventory reversal reflects weaker demand.",
  "day5_confidence": "MEDIUM"
}